Ignite Creation Date:
2025-12-25 @ 4:58 AM
Ignite Modification Date:
2025-12-26 @ 3:58 AM
Study NCT ID:
NCT05271318
Status:
RECRUITING
Last Update Posted:
2025-11-03
First Post:
2022-02-04
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
Sponsor:
TILT Biotherapeutics Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-05-17
Start Date Type:
ACTUAL
Primary Completion Date:
2027-03
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-08
Completion Date Type:
ESTIMATED
First Submit Date:
2022-02-04
First Submit QC Date:
None
Study First Post Date:
2022-03-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-30
Last Update Post Date:
2025-11-03
Last Update Post Date Type:
ESTIMATED